Australian biotech Prescient Therapeutics has signed an agreement with US-based pharmaceutical services solutions company Thermo Fisher Scientific to accelerate development and commercialization of a scalable version of its OmniCAR cell therapy platform.
The development plan will evaluate the potential of employing automated, closed cell therapy solutions to manufacture cell therapies on the platform using non-viral methods. Prescient aims to develop the next generation of OmniCAR cells with greater efficiency, lower costs and unmatched reproducibility. It is hoped they will be suitable for tech transfer to good manufacturing practice (GMP)-licenced contract development and manufacturing companies worldwide. The research is expected to take approximately 12 months to complete.
Read more about this news here.
